ClinicalTrials.gg
CompletedNCT04503759ARKUpdated May 13, 2024

Artoss Foot and Ankle Surgery Registry

An observational study in Arthritis Foot, Trauma Injury and Deformity; Bone, sponsored by Artoss Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-13.

Sponsored by Artoss Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 58 studies in Accidental Injuries with a site in United States — 17 open to participants now, 19 under way, 1 of them phase 3. Accidental Injuries · United States.

Enrollment
9th of 21
200 · median 124
Started
2020
with 7 others
Observational
21 of 58
7 open now
Registered
27th of 58
by date
Lead sponsor
1 of 58
Artoss Inc.

Among the 58 studies in Accidental Injuries with a site in United States, this one is the 9th largest by enrollment of the 21 observational ones that give a count, is one of 8 that started in 2020, is one of 21 observational ones, and was the 27th registered.

Accidental Injuries

128 studies on the registry are indexed under Accidental Injuries; 39 are open to participants now.

Browse Accidental Injuries studies →

Open to participants now

17 of the 58 studies in Accidental Injuries with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Accidental Injuries studies recruiting now, 11 (46%) set no upper age limit and 6 (25%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Accidental Injuries with a site in United States, or all of them as a file.
02

Study summary

This prospective registry was designed as an observational study to ascertain how commercially available NanoBone products are being used by surgeons performing foot and ankle surgery which involves bone grafting, as well as determining relevant patient outcomes.

Read the detailed description

This multicenter prospective patient registry was developed with the aim of documenting how surgeons are utilizing NanoBone products in foot and ankle surgery along with relevant patient outcomes. These outcomes include radiographic measures such as fusion or graft consolidation success, instrumentation integrity, and clinical outcomes (symptom and function improvement) based on investigator and patient-based outcome assessments.

The primary objective of this study is to document and analyze the use of NanoBone products in foot and ankle surgery (as a stand-alone bone graft, no other local bone, autograft, bone graft substitute, or biologic product used) and determine both radiographic success and clinical outcomes. All product related adverse events will be documented, tabulated, and summarized.

03

Conditions studied

  • Arthritis Foot
  • Trauma Injury
  • Deformity; Bone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients in the study will be drawn from the individual surgeons' practice. Patients will be among those already scheduled for foot and ankle surgery after having failed conservative treatment, or will have had foot and ankle surgery using NanoBone products but have not completed their standard of care follow-up as determined by the surgeon's practice. In addition, the surgeon has determined that the use of a NanoBone product is or was clinically necessary for the patient. The choice of a NanoBone product, as well as the surgery, is or was independent of this research project. Only patients who have had NanoBone implanted and consent to participate and meet the inclusion-exclusion criteria will be included in the registry.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient aged 18 years or older.
  • Patient is or was diagnosed with a pathology of the foot or ankle, having failed conservative treatment, and surgeon has determined that surgery with bone graft is medically necessary.
  • The surgeon has determined that NanoBone is or was clinically indicated.
  • NanoBone will be or was used as a stand-alone bone graft (no autograft, other bone graft substitute, or biologic planned or used).
  • Patient capable of understanding the content of the Form
  • Patient willing and able to participate in the registry protocol including the surgeon's standard follow-up visits and clinical evaluations.
  • Patient who has agreed to participate in the registry by providing consent according to the applicable local law and the declaration of Helsinki.

Exclusion criteria

Exclusion Criteria:

  • Severe vascular or neurological disease
  • Uncontrolled diabetes
  • Severe degenerative disease (other than degenerative disc disease)
  • Severely impaired renal function
  • Hypercalcemia, abnormal calcium metabolism
  • Existing acute or chronic infections, especially at the site of the operation
  • Inflammatory bone disease such as osteomyelitis
  • Malignant tumors
  • Patients who are or plan to become pregnant.
  • Uncooperative patients who cannot or will not follow post-operative instruction, including individuals who abuse drugs and/or alcohol.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (actual)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • Foot and Ankle Surgery using NanoBone

    All patients in the study will be drawn from the individual surgeons' practice. Patients will be among those already scheduled for foot and ankle surgery after having failed conservative treatment, or will have had foot and ankle surgery using NanoBone products but have not completed their standard of care follow-up as determined by the surgeon's practice. In addition, the surgeon has determined that the use of a NanoBone product is or was clinically necessary for the patient. The choice of a NanoBone product, as well as the surgery, is or was independent of this research project. Only patients who have had NanoBone implanted and consent to participate and meet the inclusion-exclusion criteria will be included in the registry.

    Other: NanoBone Bone Graft Substitute

Interventions

  • OtherNanoBone Bone Graft Substitute

    Synthetic, biodegradable bone grafting material that is composed of non-sintered nanocrystalline hydroxyapatite (HA) which is embedded in a silica gel matrix (amorphous SiO2). The ratio of HA/SiO2 has been chosen to optimize the rate of biodegradation for treatment of osseous defects in human bone. NanoBone does not contain any components of animal or human origin, eliminating the possibility of transmission of infection or disease.

    Also known as: nanoHA-SiO2

06

What researchers measure

Primary outcomes

  1. Radiographic Success

    Fusion/Graft Consolidation: Evidence of bony (osseous) bridging between the graft material and the patient's bone in the segment requiring fusion or reconstruction.

    Time frame: 6-months

Secondary outcomes

  1. Safety Evaluation

    Occurrence of Complications or Adverse Events

    Time frame: 6-months

Other outcomes

  1. Clinical Success

    Change from baseline in Visual Analog Scale (VAS) pain score (0=no pain, 10=worst possible pain

    Time frame: 6-months

  2. Function

    Change from baseline in Foot and Ankle Ability Measure (FAAM)

    Time frame: 6-months

07

Study locations

8 sites
  • Phoenix Foot and Ankle Institute
    Scottsdale, Arizona 85251, United States
  • Florida Orthopedic Foot & Ankle Center
    Sarasota, Florida 34239, United States
  • Illinois Orthopedic Institute
    Joliet, Illinois 60435, United States
  • Morrison Hospital
    Morrison, Illinois 61270, United States
  • Podiatry Associates of Indiana
    Indianapolis, Indiana 46254, United States
  • Hoosier Foot and Ankle
    Kokomo, Indiana 46901, United States
  • The Iowa Clinic
    West Des Moines, Iowa 50266, United States
  • Orthopedic Associates of Duluth
    Duluth, Minnesota 55805, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in May 2024, 45 months.

Of 39 observational studies under Accidental Injuries, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 60. This study's 45 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2020
First posted
Aug 7, 2020
StartActual
Aug 1, 2020
Primary completionActual
May 10, 2024
CompletionActual
May 10, 2024
Last update
May 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04503759
Lead sponsor
Artoss Inc.
Responsible party
Sponsor
First posted
Aug 7, 2020
Start date
Aug 1, 2020
Primary completion
May 10, 2024
Completion
May 10, 2024
Last update
May 13, 2024

Study contacts

Jim Cassidy, PhD
study director · Artoss Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion